Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID 24 HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID 24 HR.
PANTOPRAZOLE SODIUM vs PREVACID 24 HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
15 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor